Dr. David P. Nowotnik, Ph.D. has over 40 years experience in pharmaceutical R&D, quality systems, and regulatory affairs, and has been currently Senior Vice President of Research and Development of Abeona Therapeutics Inc. (formerly known as PlasmaTech Biopharmaceuticals, Inc.), since 1998. From 1994 to 1998, he was with Guilford Pharmaceuticals, Inc. in the position of Senior Director of Product Development where he was responsible for a team of scientists developing polymeric controlled-release drug delivery systems. From 1988 to 1994, he was with Bristol-Myers Squibb researching and developing technetium radiopharmaceuticals and MRI contrast agents. From 1977 to 1988, he was with Amersham International leading the project that resulted in the discovery and development of Ceretec, a brain perfusion diagnostic agent. He has served in a senior capacity at top pharma companies, including Tate & Lyle and Aspro-Nicholas. He received his PhD in Organic Chemistry from University of London.